An International Observational Study of Outpatients with SARS-CoV-2 Infection
How does COVID-19 progress in adults that test positive for the virus but that don't need to be immediately admitted to hospital?
What is this study about?
SARS-CoV-2 is a coronavirus that emerged in China in late 2019 causing a novel Corona-Virus Induced Disease (COVID-19). While a proportion of people with COVID-19 have sufficiently severe symptoms to require hospitalization at the time of initial symptom onset, in others the disease may remain mild, and in some cases there has been observed a worsening of symptoms a few days after initial presentation with relatively mild symptoms. There was an urgent need for understanding the progression of disease for individuals with SARS-CoV-2 infection/COVID-19 who did not require immediate hospitalization. The general aim of this study was therefore to estimate the rate of disease progression for adults who seek testing and test positive for SARS-CoV-2.
Type of study
Who is funding the study?
National Institute of Allergy and Infections, USA (NIAID)
When is it taking place?
The trial enrolled participants from May 2020 – December 2021.
Where is it taking place?
This was an international study that took place in a number of countries including the USA, Argentina, Australia, Brazil, Indonesia, Mexico, Singapore, South Africa, Peru, Europe and the UK.
Who is included?
To be eligible for enrolment, participants were ≥ 18 years of age, could not be hospitalised (outpatients), and have had signed informed consent. Participants with SARS-CoV-2 infection were followed for 28 days.